Drug intelligence / Profile preview

PDsol 12

Development stage: Phase 3
Lead developer: Fresenius Medical Care
Administration: Intraperitoneal

Overview

**PDsol 12** is an investigational low-sodium peritoneal dialysis solution developed by Fresenius Medical Care for use in patients receiving continuous ambulatory or automated peritoneal dialysis. It was evaluated against Gambrosol Trio 40 in a randomized study in hypertensive patients with chronic kidney failure. By lowering sodium exposure in a prescribed dialysis exchange, the solution was intended to enhance net sodium removal while maintaining fluid removal, thereby improving sodium and water balance and potentially reducing blood pressure or antihypertensive medication requirements.

Beyond the preview

Go deeper on PDsol 12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDsol 12.

Explore the full profile